LAUSR

1. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369: 111-121. 2. Nagendra S, Meyerson H, Skallerud G, et al. Leukemias resembling acute promyelocytic leukemia, microgranular variant. Am J Clin Pathol. 2002;117:651-657. 3. Kato M, Osumi T, Tsujimoto S, et al. RARB translocations in acute promyelocytic leukemia without Rara translocation. Blood. 2018; 78(16):4452-4458. https://doi.org/10.1158/0008-5472.CAN-180840 4. Such E, Cervera J, Valencia A, et al. A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood. 2011;117:242-245. 5. Ha JS, Do YR, Ki CS, et al. Identification of a novel PML-RARG fusion in acute promyelocytic leukemia. Leukemia. 2017;31:1992-1995. 6. Liu TH, Wen LJ, Yuan HJ, et al. Identification of novel recurrent CPSF6-RARG fusions in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood. 2018;131:1870-1873. 7. Qin YZ, Huang XJ, Zhu HH. Identification of a novel CPSF6-RARG fusion transcript in acute myeloid leukemia resembling acute promyelocytic leukemia. Leukemia. 2018;32:2285-2287. 8. Zhao J, Liang JW, Xue HL, et al. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia. Leukemia. 2019;33:1387-1399. https://doi.org/10.1038/s41375-0180338-z 9. Miller CA, Tricarico C, Skidmore ZL, et al. A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion. Blood Adv. 2018;2:1295-1299. 10. Baaske DM, Heinstein P. Cytotoxicity and cell cycle specificity of homoharringtonine. Antimicrob Agents Chemother. 1977;12: 298-300. 11. Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia. 1992;6:1189-1191. 12. de Lavallade H, Khorashad JS, Davis HP, et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood. 2007;110: 2779-2780. 13. Feldman EJ, Seiter KP, Ahmed T, et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia. 1996;10:40-42. 14. Zhang WG, Wang FX, Chen YX, et al. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2008;83:185-188. SUPPORTING INFORMATION